Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/Neurosurgerymedical mutual - ohio Duvyzat Prior Auth | OpenPay…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Duvyzat

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing prior-authorization recommended pharmacy benefit coverage of Duvyzat (givinostat) for treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older, including initial and continuing therapy clinical criteria, approval durations, documentation and conditions not recommended for approval.

    Policy Summary
    Payermedical mutual - ohio
    PolicyDuvyzat
    Policy CodePolicy N/A
    Change TypeAnnual review (no material changes)
    Effective Date
    Last ReviewMar 19, 2026
    Next Review Date
    Key ActionPrior authorization is recommended for pharmacy benefit coverage of Duvyzat; provide required documentation including baseline function tests and baseline platelet and triglyceride values, and document specialist prescribing/consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material changes

    1Covered Indication (DMD)
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval Durations (initial/extended, years)
    >=6Age Threshold (years)

    Coverage Summary

    Coverage stance: covered_with_criteria. Scope: prior-authorization recommended pharmacy benefit coverage of Duvyzat (givinostat) for Duchenne muscular dystrophy (DMD) in patients aged >= 6 years, describing initial and continuing therapy criteria, documentation requirements, approval durations, and conditions not recommended for approval. Subject: Duvyzat (givinostat) for Duchenne muscular dystrophy. Key thresholds: age >= 6 years; stable systemic corticosteroid therapy for initial approval >= 6 months; established on medication for continuation >= 1 year. Approval durations: initial approval 1 year, extended approval 1 year.

    Initial Therapy Criteria

    Duchenne Muscular Dystrophy (DMD) - Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • A: The patient is 6 years and older>= 6 years
    • B: Patient's diagnosis of Duchenne Muscular Dystrophy is confirmed by genetic testing with a confirmed pathogenic variant in the dystrophin gene
    • C: The patient has completed baseline function tests (e.g. time to wheelchair assistance, required respiratory assistance/pulmonary function tests, four-stair climb [4SC], 6-minute walk test [6MWT], time to walk/run 10 meters [10MWT], or North Star Ambulatory Assessment [NSAA])

      Examples provided; documentation of baseline function tests required

    • D: The patient is ambulatory
    • E: The patient has been a stable on a systemic corticosteroid therapy for at least 6 months>= 6 months
    • F: The medication is prescribed by or in consultation with a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders

      Initial approval requires specialist prescribing or consultation

    • G: The prescribing physician has obtained and evaluated baseline platelet counts and triglycerides levels prior to initiation

      Baseline labs required

    Baseline function tests: Examples include time to wheelchair assistance, required respiratory assistance/pulmonary function tests, 4-stair climb (4SC), 6-minute walk test (6MWT), 10-meter walk/run (10MWT), and North Star Ambulatory Assessment (NSAA).

    Continuation Therapy Criteria

    Duchenne Muscular Dystrophy (DMD) - Continuing Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • A: The patient has been established on the medication for at least 1 year>= 1 year
    • B: The patient is 6 years and older>= 6 years
    • C: The patient is ambulatory

    Conditions Not Recommended for Approval

    Conditions Not Recommended for Approval

    Not recommended when ANY of the following apply:

    ANY of the following

    • 1: Treatment in patients who have previously received gene therapy for DMD (safety/efficacy not studied)
    • 2: Concomitant treatment with exon-skipping therapies for DMD (examples: Amondys/casimersen, Exondys 51/eteplirsen, Viltepso/viltolarsen, Vyondys 53/golodirsen)
    • 3: Use for circumstances not listed in the Recommended Authorization Criteria (requests for other uses will be reviewed case-by-case)

    Provider Actions / Prior Authorization

    Prior Authorization

    Prior authorization recommended

    Prior authorization is recommended for pharmacy benefit coverage of Duvyzat; requests for non-listed uses will be reviewed for medical necessity on a case-by-case basis.

    Documentation Required

    Specialist prescribing/consultation requirement

    Initial therapy must be prescribed by or in consultation with a physician who specializes in DMD and/or neuromuscular disorders; documentation of specialist involvement should be provided.

    Documentation Required

    Baseline testing required

    Obtain and evaluate baseline platelet counts and triglyceride levels prior to initiation; complete baseline function tests (examples provided) must be documented.

    Applicable Codes

    No specific billing codes (NDC, CPT, HCPCS) are listed in this policy. Code lookup and submission should follow the payer's billing guidance and pharmacy benefit billing procedures.

    Clinical Evidence & References

    EPIDYSPhase 3 randomized, double‑blind, placebo‑controlled trial (Lancet Neurol. 2024)
    Prescribing PIDuvyzat oral suspension prescribing information, March 2024

    Evidence: EPIDYS phase 3 randomized placebo-controlled trial (Lancet Neurol. 2024); Duvyzat oral suspension prescribing information, March 2024.

    Background

    Background: Duvyzat (givinostat) is an oral histone deacetylase (HDAC) inhibitor indicated for treatment of Duchenne muscular dystrophy in patients 6 years and older. It is intended to improve muscle function and reduce inflammation, and is the first nonsteroidal treatment approved for patients with all genetic variants of DMD.

    Age>= 6 years
    Stable systemic corticosteroid therapy (initial)>= 6 months
    Established on medication (continuation)>= 1 year

    Revision History

    2026-03-19Last reviewLatest

    Policy reviewed on 03/19/2026 (annual review date and last revised date).

    Policy Summary
    Payermedical mutual - ohio
    PolicyDuvyzat
    Policy CodePolicy N/A
    Change TypeAnnual review (no material changes)
    Effective Date
    Last ReviewMar 19, 2026
    Next Review Date
    Key ActionPrior authorization is recommended for pharmacy benefit coverage of Duvyzat; provide required documentation including baseline function tests and baseline platelet and triglyceride values, and document specialist prescribing/consultation.
    SourceLink
    On This Page
    Coverage SummaryInitial Therapy CriteriaContinuation Therapy CriteriaConditions Not Recommended for ApprovalProvider Actions / Prior AuthorizationApplicable CodesClinical Evidence & ReferencesBackgroundRevision History
    D: The patient continues to be stable on a systemic corticosteroid therapy
  1. E: The medication is prescribed by or in consultation with a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders
  2. F: According to the prescriber, the patient continues to benefit from therapy, as demonstrated by a stabilization or slowed decline on timed function tests (e.g., 4-stair climb, 6-minute walk test, time-to-rise) or in the North Star Ambulatory Assessment (NSAA) score

    Prescriber attestation of clinical benefit required

    • Platelet counts prior to initiation
    • Triglyceride levels prior to initiation
    • Baseline function tests (examples: time to wheelchair assistance, required respiratory assistance/pulmonary function tests, four-stair climb [4SC], 6-minute walk test [6MWT], time to walk/run 10 meters [10MWT], North Star Ambulatory Assessment [NSAA])
    Documentation Required

    Ongoing benefit attestation for continuation

    For reauthorization, prescriber must attest the patient continues to benefit, demonstrated by stabilization or slowed decline on timed function tests or NSAA score.

    Denial Risk

    Coverage denial for non-medically necessary or investigational uses

    The Company may deny reimbursement if the drug or services are not medically necessary, investigational/experimental, not within member benefits, or if requested documentation is not provided.